Commonwealth Equity Services’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Commonwealth Equity Services’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-212	Closed	-$12K	–	3290
2020 Q3	$12K	Buy	+212	New	+$18.9K	﹤0.01%	3032
2019 Q4	–	Sell	-56	Closed	-$6K	–	2965
2019 Q3	$6K	Sell	56 -50	-47%	-$10.1K	﹤0.01%	2830
2019 Q2	$31K	Sell	106 -50	-32%	-$20.9K	﹤0.01%	2721
2019 Q1	$70K	Hold	156	–	–	﹤0.01%	2642
2018 Q4	$71K	Hold	156	–	–	﹤0.01%	2535
2018 Q3	$141K	Buy	156 +6	+4%	+$3.96K	﹤0.01%	2590
2018 Q2	$88K	Buy	150 +25	+20%	+$16.3K	﹤0.01%	2615
2018 Q1	$81K	Buy	125 +50	+67%	+$37.5K	﹤0.01%	2561
2017 Q4	$27K	Hold	75	–	–	﹤0.01%	2608
2017 Q3	$23K	Buy	+75	New	+$28.5K	﹤0.01%	2522

Other funds holding HTGM

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Commonwealth Equity Services's HTGM Position: Q4 2020 in Review

Commonwealth Equity Services sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2020, closing a stake of 212 shares — an estimated $12K sold.

Commonwealth Equity Services first reported a position in HTGM in Q3 2017 and held it in 10 quarters. The position peaked at $141K in Q3 2018. 23 funds tracked by Wall St. Rank hold HTGM as of Q4 2020.

Commonwealth Equity Services reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Commonwealth Equity Services sold 212 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2020, an estimated $12K.
Commonwealth Equity Services first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
Commonwealth Equity Services's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $141K in Q3 2018.
23 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2020.

Based on Commonwealth Equity Services's 13F filing for Q4 2020, filed 11 Feb 2021.